

ASX Announcement

Thursday, 9 November 2023

**Notice under ASX Listing Rule 3.10A**

Tissue Repair Limited (ASX:TRP) (**Tissue Repair** or the **Company**) advises that, in accordance with ASX Listing Rule 3.10A, the following securities will be released from mandatory escrow, noting 4,656,830 ordinary shares remain voluntary escrowed until 18 May 2024.

Number of securities	Type of security	Escrow Release Date
9,027,658	Fully paid ordinary shares	18 November 2023
4,656,830 <sup>1</sup>	Fully paid ordinary shares	18 May 2024
3,964,240	Options	18 November 2023

<sup>1</sup>Securities remain voluntary escrowed until 18 May 2024, 30 months from Official Quotation.

Further, in accordance with ASX Listing Rule 3.10A, the following securities will be released from voluntary escrow:

Number of securities	Type of security	Escrow Release Date
14,415,408	Fully paid ordinary shares	18 November 2023
3,549,072	Options	18 November 2023

The release of the shares from escrow does not change the issued capital of the Company.

A summary of securities on issue is outlined in the table below:

Number of securities	Security details
55,808,013	Fully paid ordinary shares
4,656,830	Fully paid ordinary shares – Escrowed until 18 May 2024
1,700,000	Options – Exercise price \$0.2055, Expire 30.12.2033
1,430,000	Options – Exercise price \$0.3715, Expire 30.8.2034
1,265,000	Options – Exercise price \$0.3715, Expire 1.10.2034
3,919,292	Options – Exercise price \$1.15, Expire 15.11.2036
9,540,000	Options – Exercise price \$0.2055, Expire 30.12.2033 (Escrowed until 18 May 2024)
1,600,000	Options – Exercise price \$1.15, Expire 15.11.2036 (Escrowed until 18 May 2024)
2,500,000	Options – Exercise price \$0.3715, Expire 30.8.2034 (Escrowed until 18 May 2024)

For further information in relation to this release please contact Darryl Reed at [darryl.reed@trtherapeutics.com](mailto:darryl.reed@trtherapeutics.com) 0419 557 663.



**Tissue Repair Ltd**

Level 10, 255 Pitt Street, Sydney, NSW 2000

ACN: 158 411 566



This announcement has been approved for release by TRP's Chair.

--ENDS--

**About Tissue Repair**

Tissue Repair Limited (ASX:TRP) is a Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987<sup>®</sup>, with a secondary focus on commercialising TR Pro+<sup>™</sup> a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures. The Company's longer-term strategy is to commercialise its propriety Glucoprime<sup>®</sup> API to treat a variety of wounds and skin conditions.



**Tissue Repair Ltd**

Level 10, 255 Pitt Street, Sydney, NSW 2000

ACN: 158 411 566